442 related articles for article (PubMed ID: 11034410)
1. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
Brodbeck WG; Mold C; Atkinson JP; Medof ME
J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
[TBL] [Abstract][Full Text] [Related]
2. Complement alternative pathway activation and control on membranes of human lymphoid B cell lines.
Caudwell V; Porteu F; Calender A; Pangburn MK; Halbwachs-Mecarelli L
Eur J Immunol; 1990 Dec; 20(12):2643-50. PubMed ID: 1702720
[TBL] [Abstract][Full Text] [Related]
3. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
[TBL] [Abstract][Full Text] [Related]
4. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.
Barilla-LaBarca ML; Liszewski MK; Lambris JD; Hourcade D; Atkinson JP
J Immunol; 2002 Jun; 168(12):6298-304. PubMed ID: 12055245
[TBL] [Abstract][Full Text] [Related]
5. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
6. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Lublin DM; Coyne KE
J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
8. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
9. Diversity of sites for measles virus binding and for inactivation of complement C3b and C4b on membrane cofactor protein CD46.
Iwata K; Seya T; Yanagi Y; Pesando JM; Johnson PM; Okabe M; Ueda S; Ariga H; Nagasawa S
J Biol Chem; 1995 Jun; 270(25):15148-52. PubMed ID: 7541036
[TBL] [Abstract][Full Text] [Related]
10. Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation.
Christiansen D; Loveland B; Kyriakou P; Lanteri M; Rubinstein E; Gerlier D
Mol Immunol; 2000; 37(12-13):687-96. PubMed ID: 11275254
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line.
Bjørge L; Jensen TS; Matre R
Cancer Immunol Immunother; 1996 Mar; 42(3):185-92. PubMed ID: 8640847
[TBL] [Abstract][Full Text] [Related]
12. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
Mold C; Walter EI; Medof ME
J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
[TBL] [Abstract][Full Text] [Related]
13. Functional properties of membrane cofactor protein of complement.
Seya T; Atkinson JP
Biochem J; 1989 Dec; 264(2):581-8. PubMed ID: 2481448
[TBL] [Abstract][Full Text] [Related]
14. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
Matsumoto M; Sugita Y; Seya T
Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
[TBL] [Abstract][Full Text] [Related]
15. Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H.
Pangburn MK
Immunology; 1990 Dec; 71(4):598-600. PubMed ID: 1703989
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
17. Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation.
Devaux P; Christiansen D; Fontaine M; Gerlier D
Eur J Immunol; 1999 Mar; 29(3):815-22. PubMed ID: 10092084
[TBL] [Abstract][Full Text] [Related]
18. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro.
Christiansen D; Milland J; Thorley BR; McKenzie IF; Loveland BE
Eur J Immunol; 1996 Mar; 26(3):578-85. PubMed ID: 8605924
[TBL] [Abstract][Full Text] [Related]
19. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation.
Seya T; Hara T; Matsumoto M; Akedo H
J Immunol; 1990 Jul; 145(1):238-45. PubMed ID: 1694203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
